+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Evaluation of a new beta adrenoceptor agonist procaterol based on metabolic responses in rats

Biochemical Pharmacology 27(21): 2531-2536
Evaluation of a new beta adrenoceptor agonist procaterol based on metabolic responses in rats
I.v. injection of 5-(1-hydroxy-2-isopropylaminobutyl)-8-hydroxycarbostyril hydrochloride hemihydrate (procaterol) or isoproterenol into fasted rats caused increases in blood levels of glucose, lactate, free fatty acids (FFA), glycerol, immunoreactive insulin and cAMP. Procaterol-induced alterations of these metabolic parameters, other than FFA, were durable; the increases were observable over a period longer than 2 h, in contrast to a much shorter duration of isoproterenol-induced metabolic changes. These actions of procaterol were antagonized by propranolol, were observed in adrenodemedullated rats, and were enhanced by theophylline. Metabolic changes induced by procaterol might actually be mediated via .beta.-adrenoceptors as well as its pharmacological actions. Procaterol caused hyperlactacidemia at M doses 10-100 times lower than those required for isoproterenol, trimetoquinol or salbutamol. A much higher dose of procaterol was required to increase blood levels of FFA, glycerol and insulin. Butoxamine, a selective .beta.2-adrenoceptor antagonist, antagonized the isoproterenol-induced blood lactate, while practolol, a selective .beta.1-antagonist, effectively inhibited the stimulatory actions of isoproterenol on FFA, glycerol and insulin. Procaterol was a more selective .beta.2-adrenoceptor agonist than isoproterenol or trimetoquinol and was more potent than salbutamol.

Accession: 005395340

PMID: 31885

Related references

Responses to the beta 2-selective agonist procaterol of vascular and atrial preparations with different functional beta-adrenoceptor populations. British Journal of Pharmacology 84(1): 227-235, 1985

Metabolic responses to a new beta-adrenoceptor agonist, ICI 118,587, in conscious rats. Pharmacology 27(4): 202-210, 1983

Agonist-induced desensitization of beta-adrenoceptor function in humans. Subtype-selective reduction in beta 1- or beta 2-adrenoceptor-mediated physiological effects by xamoterol or procaterol. Circulation 81(3): 914-921, 1990

Long term in vivo regulation of human beta 2 adrenoceptor function by procaterol a selective beta 2 adrenoceptor agonist. Naunyn-Schmiedeberg's Archives of Pharmacology 335(SUPPL): R87, 1987

Metabolic responses to a new beta adrenoceptor agonist ici 118587 racemic 1 4 hydroxyphenoxy 3 2 4 morpholinecarboxamidoethylamino propan 2 ol in conscious rats. Pharmacology (Basel) 27(4): 202-210, 1983

A comparative study of a new selective beta 2-adrenoceptor agonist, procaterol and salbutamol in asthma. British Journal of Clinical Pharmacology 19(6): 787-791, 1985

Facilitation by procaterol, a beta-adrenoceptor agonist, of noradrenaline release in the pithed rat independently of angiotensin II formation. British Journal of Pharmacology 113(3): 781-788, 1994

Effect of procaterol, a beta 2-adrenoceptor agonist, on skin whealing response caused by inflammatory mediators in asthmatic children. Annals of Allergy, Asthma & Immunology 75(2): 139-141, 1995

An investigation of the beta-adrenoceptor that mediates metabolic responses to the novel agonist BRL28410 in rat soleus muscle. Biochemical Pharmacology 37(5): 947-950, 1988

Ability of inhaled procaterol, a beta 2 adrenoceptor agonist, to attenuate eicosanoid-induced airflow obstruction and airway microvascular leakage. Clinical and Experimental Allergy 25(4): 371-378, 1995